Daré Bioscience to Present at the 2021 BIO CEO & Investor Digital Conference

Rhea-AI Summary

Daré Bioscience, a leader in women’s health, announced that CEO Sabrina Martucci Johnson will present at the BIO CEO & Investor Digital Conference from February 16-18, 2021. The presentation will cover innovative developments in women's health, including Daré's unique product portfolio.

Following the event, a recording will be available on Daré's investor relations website until March 4, 2021. The company focuses on developing differentiated therapies in contraception, vaginal health, sexual health, and fertility.

SAN DIEGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will present at the BIO CEO & Investor Digital Conference that will take place virtually February 16 – 18, 2021.

Following the conclusion of the event, a recording of Ms. Johnson’s presentation will be available for on-demand listening under “Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com until March 4, 2021.

About Daré Bioscience

Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.

Daré’s product portfolio includes potential first-in-category candidates in clinical development: Ovaprene®, a hormone-free, monthly contraceptive intravaginal ring whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra®; DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy following menopause. To learn more about Daré’s full portfolio of women’s health product candidates, and mission to deliver differentiated therapies for women, please visit www.darebioscience.com.

Daré may announce material information about its finances, product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted on the investor relations page of Daré’s website mentioned above.

Contact:

Investors on behalf of Daré Bioscience, Inc.:
Tom Masterson
Allele Capital Partners
tmasterson@allelecapital.com
646.573.3216

Source: Daré Bioscience, Inc.

FAQ

What is the date of the BIO CEO & Investor Digital Conference for Daré Bioscience?

Daré Bioscience will present at the BIO CEO & Investor Digital Conference from February 16-18, 2021.

Who is the CEO of Daré Bioscience presenting at the conference?

Sabrina Martucci Johnson is the President and CEO of Daré Bioscience presenting at the conference.

How can I access the presentation by Daré Bioscience after the conference?

The recording of Daré Bioscience’s presentation will be available on their investor relations website until March 4, 2021.

What areas does Daré Bioscience focus on in women's health?

Daré Bioscience focuses on contraception, vaginal health, sexual health, and fertility.

What innovative products is Daré Bioscience developing?

Daré Bioscience is developing products like Ovaprene, Sildenafil Cream, DARE-BV1, and DARE-HRT1.